Cardinal Health has added a high-capacity production line for actinium-225 (Ac-225) at its Center for Theranostics Advancement in Indianapolis, expanding its supply of the radioisotope for use in investigational and commercial targeted alpha therapies.
Since launching routine Ac-225 production at scale in late 2024, the company said it has quadrupled its weekly output and expects to continue increasing capacity through 2026 with a $150 million investment over the next three years. To date, Cardinal Health's Ac-225 has supported more than 15 clinical trials worldwide, the firm noted.
Ac-225 is an alpha-emitting radionuclide that can be linked to molecules designed to selectively target cancer cells. Drug products incorporating the isotope are in development for prostate, neuroendocrine, breast, colon, melanoma, and lymphoma cancers, according to the company.
